Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
CVS Health funds insomnia app, stop smoking support could followThe influential US pharmacy benefit manager CVS Health has said it will fund an insomnia app, allowing it Share XCVS Health funds insomnia app, stop smoking support could followhttps://pharmaphorum.com/news/cvs-health-funds-insomnia-app-stop-smoking-and-abuse-support-could-follow/
AbbVie makes case for Humira follow-on upadacitinib at EULARThe summer medical conference season is well and truly upon us and much of the focus this week Share XAbbVie makes case for Humira follow-on upadacitinib at EULARhttps://pharmaphorum.com/news/abbvie-makes-case-for-humira-follow-on-upadacitinib-at-eular/
Catalyst squares up to FDA over rival drug approvalCatalyst Pharma is suing the FDA over its approval of a potential rival to its rare disease therapy Share XCatalyst squares up to FDA over rival drug approvalhttps://pharmaphorum.com/news/catalyst-squares-fda-rival-drug-approval/
FDA approves Roche’s $90,000 lymphoma combinationThe FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – Share XFDA approves Roche’s $90,000 lymphoma combinationhttps://pharmaphorum.com/news/fda-approves-roches-90000-lymphoma-combination/
Woodford’s woes could cause biotech fire-saleThis week’s news has been dominated by the downfall of ‘rock star’ investment manager Neil Woodford, who has Share XWoodford’s woes could cause biotech fire-salehttps://pharmaphorum.com/news/woodfords-woes-could-cause-biotech-fire-sale/
Sanofi appoints former Novartis exec Hudson as CEOSanofi has appointed Novartis’ pharma chief Paul Hudson as chief executive to replace the retiring Olivier Brandicourt, prompting Share XSanofi appoints former Novartis exec Hudson as CEOhttps://pharmaphorum.com/news/sanofi-appoints-former-novartis-exec-hudson-as-ceo/
Orkambi parents start ‘buyers club’ to import generic version of CF drugA group of parents in the UK have taken matters into their own hands in an effort to Share XOrkambi parents start ‘buyers club’ to import generic version of CF drughttps://pharmaphorum.com/news/orkambi-parents-start-buyers-club-to-import-generic-version-of-cf-drug/
Sanofi trumpets Darzalex rival isatuximab in refractory myelomaSanofi’s plans for a comeback in cancer have taken a step forward with new data on its anti-CD38 Share XSanofi trumpets Darzalex rival isatuximab in refractory myelomahttps://pharmaphorum.com/news/sanofi-darzalex-rival-isatuximab-refractory-myeloma/
